

Supplemental Tables for:
 Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in HR+, HER2- Advanced Breast Cancer after Endocrine Therapy
 Gregory L. Price et al.

Supplemental Table S1. Patient compliance (%) for the mBPI-sf, EORTC QLQ-C30 and EORTC QLQ-BR23 by study arm and visit.

Planned visit	Main reason if not compliant	Abemaciclib	Placebo +	Abemaciclib	Placebo +	Abemaciclib	Placebo +
		+ fulvestrant n=441	fulvestrant n=223	+ fulvestrant n=441	fulvestrant n=223	+ fulvestrant n=441	fulvestrant n=223
		mBPI-sf		EORTC QLQ-C30		EORTC QLQ-BR23	
Baseline		95.5	97.8	97.7	98.2	97.7	98.7
	Missing	1.1	0.4	0.5	0.0	0.5	0.0
	Other	1.6	0.4	0.2	0.9	0.2	0.4
	Study site failed to administer	1.6	1.3	1.1	0.9	1.1	0.9
	Subject refusal	0.2	0.0	0.5	0.0	0.5	0.0
Cycle 2		94.6	92.6	96.4	94.4	95.4	94.0
	Missing	0.5	0.9	0.2	0.5	0.2	0.0

	Other	1.9	1.9	1.0	0.5	1.2	0.9
	Study site failed to administer	2.4	3.2	1.9	3.7	2.7	3.7
	Subject refusal	0.5	1.4	0.5	0.9	0.5	1.4
Cycle 3		95.3	93.9	96.9	96.9	96.1	95.9
	Missing	0.3	0.5	0.3	0.5	0.3	0.5
	Other	1.8	1.5	0.8	0.0	1.3	0.5
	Study site failed to administer	1.6	3.1	1.3	2.0	1.6	2.6
	Subject refusal	1.0	0.5	0.8	0.5	0.8	0.5
Cycle 5		95.8	95.0	96.7	96.9	96.4	98.1
	Missing	0.0	0.0	0.0	0.0	0.0	0.0
	Other	2.1	1.3	1.5	0.6	1.5	0.0
	Study site	1.2	1.9	0.9	1.3	1.2	0.6

	failed to administer						
	Subject refusal	0.9	1.9	0.9	1.3	0.9	1.3
Cycle 7		93.5	97.0	94.5	97.8	94.1	97.0
	Missing	0.0	0.0	0.0	0.0	0.3	0.0
	Other	2.3	1.5	2.0	0.7	2.0	0.7
	Study site failed to administer	2.0	0.0	1.6	0.0	1.6	0.7
	Subject refusal	2.3	1.5	2.0	1.5	2.0	1.5
Cycle 9		95.0	95.6	95.0	97.4	95.7	96.5
	Missing	0.0	0.0	0.0	0.0	0.0	0.0
	Other	1.1	0.9	1.4	0.0	1.1	0.9
	Study site failed to administer	2.1	2.6	2.1	2.6	1.8	2.6

	Subject refusal	1.8	0.9	1.4	0.0	1.4	0.0
Cycle 11		95.8	97.0	95.8	97.0	95.4	97.0
	Missing	0.4	0.0	0.4	0.0	0.4	0.0
	Other	0.4	1.0	0.4	1.0	0.4	1.0
	Study site failed to administer	2.7	0.0	2.7	0.0	3.1	0.0
	Subject refusal	0.8	2.0	0.8	2.0	0.8	2.0
Cycle 13		96.3	97.8	97.1	97.8	96.7	97.8
	Missing	0.0	0.0	0.0	0.0	0.0	0.0
	Other	0.8	0.0	0.4	0.0	0.4	0.0
	Study site failed to administer	2.5	2.2	2.1	2.2	2.1	2.2
	Subject refusal	0.4	0.0	0.4	0.0	0.8	0.0

Cycle 16		91.4	94.6	92.4	94.6	91.9	94.6
	Missing	1.0	4.1	1.0	4.1	1.0	4.1
	Other	2.4	0.0	2.4	0.0	2.4	0.0
	Study site failed to administer	3.8	1.4	3.3	1.4	3.8	1.4
	Subject refusal	1.4	0.0	1.0	0.0	1.0	0.0
Cycle 19		94.6	100.0	95.3	100.0	95.3	100.0
	Missing	1.4	0.0	1.4	0.0	1.4	0.0
	Other	1.4	0.0	0.7	0.0	0.7	0.0
	Study site failed to administer	2.7	0.0	2.7	0.0	2.7	0.0
	Subject refusal	0.0	0.0	0.0	0.0	0.0	0.0
Cycle 22		96.7	85.7	96.7	85.7	97.8	85.7
	Missing	0.0	3.6	0.0	3.6	0.0	3.6

	Other	0.0	0.0	0.0	0.0	0.0	0.0
	Study site failed to administer	2.2	10.7	3.3	10.7	2.2	10.7
	Subject refusal	1.1	0.0	0.0	0.0	0.0	0.0
Cycle 25		98.1	100.0	98.1	100.0	98.1	100.0
	Missing	1.9	0.0	1.9	0.0	1.9	0.0
	Other	0.0	0.0	0.0	0.0	0.0	0.0
	Study site failed to administer	0.0	0.0	0.0	0.0	0.0	0.0
	Subject refusal	0.0	0.0	0.0	0.0	0.0	0.0
Cycle 28		96.0	100.0	96.0	100.0	96.0	100.0
	Missing	0.0	0.0	0.0	0.0	0.0	0.0
	Other	0.0	0.0	0.0	0.0	0.0	0.0
	Study site	4.0	0.0	4.0	0.0	4.0	0.0

	failed to administer						
	Subject refusal	0.0	0.0	0.0	0.0	0.0	0.0
Post-discontinuation Follow-up		77.9	78.5	77.1	82.3	78.4	82.3
	Missing	0.0	0.0	0.0	0.0	0.0	0.0
	Other	8.5	8.9	8.1	7.6	8.5	7.6
	Study site failed to administer	5.5	7.0	6.8	4.4	5.1	5.1
	Subject refusal	7.7	5.7	7.6	5.7	7.6	5.1

Abbreviations: EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality-of-Life Questionnaire; EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer, Quality-of-Life Questionnaire Core 30; mBPI-sf, Modified Brief Pain Inventory–short form; n, number of patients.